UroGen Pharma Ltd. financial data

Symbol
URGN on Nasdaq
Industry
Pharmaceutical Preparations
Location
9 Ha'ta'asiya St, Ra'anana, Israel
State of incorporation
Israel
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 752 % +55%
Quick Ratio 22.6 % +16.7%
Debt-to-equity 15.4K %
Return On Equity -7.36K % -6621%
Return On Assets -47.4 % +32.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46.1M shares +27.6%
Common Stock, Shares, Outstanding 42.2M shares +30%
Entity Public Float 675M USD +255%
Common Stock, Value, Issued 115K USD +29.2%
Weighted Average Number of Shares Outstanding, Basic 47M shares +30.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 90.4M USD +9.29%
Cost of Revenue 8.88M USD -5.13%
Research and Development Expense 57.1M USD +25.3%
Operating Income (Loss) -96.8M USD -47.7%
Nonoperating Income (Expense) -229K USD -127%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -124M USD -26.2%
Income Tax Expense (Benefit) 2.83M USD -27.8%
Net Income (Loss) Attributable to Parent -127M USD -24.1%
Earnings Per Share, Basic -3 USD/shares +19.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 172M USD +81%
Cash, Cash Equivalents, and Short-term Investments 242M USD +70.8%
Accounts Receivable, after Allowance for Credit Loss, Current 20.3M USD +31.5%
Inventory, Net 9.23M USD +62.6%
Assets, Current 276M USD +63.2%
Property, Plant and Equipment, Net 655K USD -4.94%
Operating Lease, Right-of-Use Asset 849K USD
Other Assets, Noncurrent 589K USD -71.1%
Assets 286M USD +60.2%
Accounts Payable, Current 10.9M USD +67.8%
Employee-related Liabilities, Current 10.6M USD -2.26%
Liabilities, Current 45.9M USD +47.2%
Operating Lease, Liability, Noncurrent 58K USD
Liabilities 295M USD +20.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 56K USD +367%
Retained Earnings (Accumulated Deficit) -806M USD -18.7%
Stockholders' Equity Attributable to Parent -8.8M USD +86.5%
Liabilities and Equity 286M USD +60.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.7M USD -23%
Net Cash Provided by (Used in) Financing Activities 54.7M USD +8046%
Net Cash Provided by (Used in) Investing Activities 13.5M USD +116%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 42.2M shares +30%
Common Stock, Par or Stated Value Per Share 0.01 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 36.4M USD
Deferred Tax Assets, Valuation Allowance 169M USD +17.4%
Deferred Tax Assets, Gross 169M USD +17.7%
Operating Lease, Liability 843K USD -49.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -127M USD -24.2%
Lessee, Operating Lease, Liability, to be Paid 882K USD -51.6%
Property, Plant and Equipment, Gross 4.94M USD +6.36%
Operating Lease, Liability, Current 785K USD -4.15%
Lessee, Operating Lease, Liability, to be Paid, Year Two 58K USD -93%
Lessee, Operating Lease, Liability, to be Paid, Year One 824K USD -12.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 39K USD -75.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 58K USD -92.6%
Deferred Tax Assets, Operating Loss Carryforwards 123M USD +18.7%
Unrecognized Tax Benefits 1.97M USD 0%
Operating Lease, Payments 277K USD -5.78%
Depreciation, Depletion and Amortization 329K USD -59%
Deferred Tax Assets, Net of Valuation Allowance 769K USD +140%
Share-based Payment Arrangement, Expense 13.1M USD +40.3%